A Phase II trial affirmed the safety and efficacy of psilocybin-assisted therapy in a group setting, with a majority experiencing sustained response and remission from depressive symptoms. A qualitative analysis of these participants underscored the acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder, highlighting the therapy’s positive impact…
